Intellectual Property Magazine
Pharma conflict cure
Maxim Sobolev examines the dilemma of secondary patents and their impact on pharma in Russia
Maxim Sobolev - Rouse
The Russian IP ombudsman Anatoly Semenov has writtento the Russian State Duma, drawing attention to the increasing number
of patent
conflicts among pharmaceutical manufacturers in Russia and urged the Duma to
legislate to address the issue.